Fosamax Osteonecrosis of the Jaw Settlement: Statute of Limitations in Pennsylvania

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Literacy to Specific Pharmaceutical Risks

For decades, general health and science information has served as the foundation for public understanding of medical risks and therapeutic benefits. This legacy context encompasses broad awareness of how medications interact with biological systems, emphasizing the importance of informed patient decision-making. Within this framework, the transition from general health literacy to specific pharmaceutical exposure concerns requires careful attention to how long-term medication use may intersect with occupational or environmental factors. In the domain of mass production, where manufacturing processes and material handling are central, the focus shifts from population-level health guidance to the practical realities of workplace exposure. Workers in pharmaceutical production, chemical processing, or related industries may encounter substances that carry distinct risk profiles when combined with certain medications. This pivot from general health context to occupational exposure concern is particularly relevant when considering bisphosphonate therapies, such as Fosamax, which have been associated with rare but serious conditions like osteonecrosis of the jaw. The statute of limitations for legal claims in Pennsylvania adds a temporal dimension to this concern, as affected individuals must navigate both medical monitoring and legal timelines. Thus, the bridge from legacy health information to occupational exposure underscores the need for integrated awareness of medication history, workplace safety protocols, and jurisdictional legal frameworks.

Fosamax and Osteonecrosis of the Jaw: Medical Evidence

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, consideration of drug discontinuation after 3 to 5 years of use is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a known adverse effect associated with bisphosphonate use, including Fosamax. ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanisms and Risk Context

The mechanistic pathways linking Fosamax to ONJ involve the drug's action on bone remodeling. Bisphosphonates inhibit osteoclast-mediated bone resorption, which can lead to reduced bone turnover and impaired healing of the jawbone, particularly after dental procedures or local infection. This disruption in normal bone metabolism may contribute to the development of necrotic bone lesions characteristic of ONJ. In terms of settlement considerations for affected patients in Pennsylvania, the statute of limitations is a critical factor. The statute of limitations for product liability claims, including those related to Fosamax and ONJ, generally begins to run from the date the injury is discovered or reasonably should have been discovered. For ONJ, this discovery date is often tied to the clinical presentation and diagnosis of the condition. Patients who have been diagnosed with ONJ after using Fosamax should be aware that the timeline between exposure to the drug and documented harm can vary widely, from days to months after starting treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability may affect the calculation of the statute of limitations, as the clock may start at different points depending on when symptoms first appeared or when a formal diagnosis was made. Adequacy of warnings regarding Fosamax and ONJ is another important risk anchor. The prescribing information for Fosamax includes a warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also identifies known risk factors and recommends discontinuation of bisphosphonate treatment for patients requiring invasive dental procedures to reduce the risk of ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the adequacy of these warnings may be questioned if patients were not adequately informed about the risk of ONJ before starting treatment, particularly given that the condition can occur spontaneously and may be associated with common dental procedures.

Legal Considerations and Statute of Limitations in Pennsylvania

For patients considering legal action, the settlement landscape for Fosamax-related ONJ claims involves evaluating the strength of the evidence linking the drug to the injury, the timing of the injury relative to drug exposure, and the adequacy of warnings provided by the manufacturer. In Pennsylvania, the statute of limitations for such claims is typically two years from the date of discovery of the injury, but this can vary based on specific circumstances. Patients should consult with a legal professional to understand how the statute of limitations applies to their individual case, especially given the potential for delayed onset of symptoms after starting Fosamax.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in Pennsylvania?

In Pennsylvania, the statute of limitations for product liability claims, including those related to Fosamax and osteonecrosis of the jaw (ONJ), is typically two years from the date the injury is discovered or reasonably should have been discovered. This discovery date is often tied to the clinical presentation and diagnosis of ONJ. Because symptoms can appear from one day to several months after starting Fosamax, the exact timeline may vary. It is important to consult with a legal professional to determine how the statute of limitations applies to your specific case.

What are the known risk factors for developing ONJ while taking Fosamax?

Known risk factors for ONJ include invasive dental procedures (such as tooth extraction, dental implants, or boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.